Volume 3 Issue 1 | 2026 | View PDF
Paper Id:IJMSM-V3I1P101
doi: 10.71141/30485037/V3I1P101

Inhalation Hydrogen Therapy in Drug-Induced Interstitial Lung Disease: A Case Report

Ooi Po Lin, Ho Gwo Fuang, Chiew Wern Way

Citation:
Ooi Po Lin, Ho Gwo Fuang, Chiew Wern Way, "Inhalation Hydrogen Therapy in Drug-Induced Interstitial Lung Disease: A Case Report" International Journal of Multidisciplinary on Science and Management, Vol. 3, No. 1, pp. 1-7, 2026.

Abstract:
Drug-induced interstitial lung disease (DIILD) is a severe complication that can arise from cancer treatment. The usual treatment approach involves high-dose glucocorticoids and supportive care. This case report aims to discuss the potential role of hydrogen therapy in managing DIILD. A 64-year-old female, diagnosed with early-stage HER2- positive breast cancer, underwent adjuvant chemotherapy. During her cycle 4 follow-up, she presented with breathlessness, initially thought to be due to pneumonia. However, her condition quickly worsened, requiring admission and ventilatory support in the intensive care unit (ICU) due to respiratory failure. CT revealed changes indicative of interstitial lung disease, prompting the initiation of high-dose glucocorticoids. Despite this, her clinical status did not improve, and she was discharged with a hydrogen/oxygen machine due to persistent oxygen desaturation and reduced physical tolerance. Two weeks after discharge, she showed significant recovery, regaining her ability to ambulate without oxygen supplementation during follow-up visits. Several studies have reported the use of hydrogen therapy for its anti-inflammatory and antioxidant properties. While some articles reported efficacy of hydrogen therapy in these diseases, it is still investigational and lacks robust scientific evidence. Based on this case, we suggest that inhalation of hydrogen therapy could be a promising treatment option for DIILD.

Keywords: Drug-induced interstitial lung disease, DIILD, Inhalation therapy, Hydrogen therapy.

References:
1. P. Conte, P. A. Ascierto, G. Patelli, "Drug-Induced Interstitial Lung Disease during Cancer Therapies: Expert Opinion on Diagnosis and Treatment," ESMO Open, vol. 7, p. 100404, 2022.
2. Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, "Common Terminology Criteria for Adverse Events (CTCAE), version 5.0," 2017.
3. C. J. Ryerson, M. Kolb, F. Bonella, et al., "An International Working Group Perspective on Variable and Progressive Pulmonary Fibrosis in Adults," American Journal of Respiratory and Critical Care Medicine, vol. 205, no. 4, pp. 407–418, 2022.
4. S. Skeoch, N. Weatherley, A. J. Swift, et al., "Drug-Induced Interstitial Lung Disease: A Systematic Review," Journal of Clinical Medicine, vol. 7, no. 10, p. 356, 2018.
5. J. Yayan, K. Rasche, and S. Noé, "Drug-Induced Interstitial Lung Disease: A Pharmacovigilance Study," Journal of Pharmaceutical Health Care and Sciences, vol. 11, p. 9, 2025.
6. M. Selman, T. E. King Jr., and A. Pardo, "Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about its Pathogenesis and Implications for Therapy," Annals of Internal Medicine, vol. 134, no. 2, pp. 136–151, 2001.
7. P. Camus, A. Fanton, P. Bonniaud, et al., "Interstitial Lung Disease Induced by Drugs and Radiation," Respiratory Research, vol. 13, p. 39, 2012.
8. P. Spagnolo, C. Vancheri, M. Kreuter, et al., "Drug-induced Interstitial Lung Disease," European Respiratory Journal, vol. 60, p. 2102776, 2022.
9. Ohsawa, M. Ishikawa, K. Takahashi, et al., "Hydrogen Acts as a Therapeutic Antioxidant by Selectively Reducing Cytotoxic Oxygen Radicals," Nature Medicine, vol. 13, pp. 688–694, 2007.
10. Y. Terasaki, I. Ohsawa, Z. Terasaki, et al., "Hydrogen Therapy Attenuates Irradiation-Induced Lung Damage by Reducing Oxidative Stress," American Journal of Physiology–Lung Cellular and Molecular Physiology, vol. 301, no. 4, pp. L415–L426, 2011.
11. C. Tang, L. Wang, Z. Chen, J. Yang, H. Gao, C. Guan, Q. Gu, S. He, F. Yang, S. Chen, L. Ma, Z. Zhang, Y. Zhao, L. Tang, Y. Xu, and Y. Hu, "Efficacy and Safety of Hydrogen Therapy in Patients with Early-Stage Interstitial lung disease: A single-center, randomized, parallel-Group Controlled Trial," Therapeutics and Clinical Risk Management, vol. 19, pp. 1051–1061, 2023.
12. National Health Commission of the People’s Republic of China, "Notice of the 7th Version of the Guidelines for the Diagnosis and Management of COVID-19," 2020.
13. Y. Yang, P. Y. Liu, W. Bao, et al., "Hydrogen Inhibits Endometrial Cancer Growth via a ROS/NLRP3/caspase-1/GSDMD-Mediated Pyroptotic Pathway," BMC Cancer, vol. 20, p. 28, 2020.
14. L. Zhao, C. Zhou, J. Zhang, et al., "Hydrogen Protects Mice from Radiation-Induced Thymic Lymphoma in BALB/c mice," International Journal of Biological Sciences, vol. 7, no. 3, pp. 297–300, 2011.
15. S. Hirano, H. Yamamoto, Y. Ichikawa, B. Sato, Y. Takefuji, and F. Satoh, "Molecular Hydrogen as a Novel Antitumor Agent: Possible Mechanisms Underlying Gene Expression," International Journal of Molecular Sciences, vol. 22, no. 16, p. 8724, 2021.